BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : S$4.38 B

According to BeiGene 's latest financial reports the company has S$4.38 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$S$4.67 B-20.5%
2022-12-31$S$5.87 B-28.95%
2021-12-31$S$8.27 B61.68%
2020-12-31$S$5.11 B288.82%
2019-12-31$S$1.31 B-44.93%
2018-12-31$S$2.38 B161.04%
2017-12-31$S$0.91 B79.18%
2016-12-31$S$0.51 B385.42%
2015-12-31$S$0.10 B209.05%
2014-12-31$S$34.04 M-169.38%
2013-12-31$-S$49.08 M

Net assets for similar companies or competitors

Company Net assets differencediff. Country
S$7.83 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.81 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA